Allogeneic bone marrow cocultured with human islets significantly improves islet survival and function in vivo

John Z Q Luo, Fang Xiong, A. Samer Al-Homsi, Camillo Ricordi, Luguang Luo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background. A significant barrier to islet transplantation is the rapid loss of human islet function in vivo. The present study evaluates whether bone marrow (BM) could be used to support human islet survival and function in vivo. Methods. We cocultured human islets and BM for 3 weeks before transplantation into the left subrenal capsule of diabetic severe combined immunodeficient mice. Results. The cocultured human islets before transplantation demonstrated improved viability, increased size, and migration capacity in vitro. After 4 months, animals transplanted with precultured BM/islets exhibited euglycemia and detectable human insulin levels (157 KU/mL), whereas no human insulin was detected in the islet-only transplantation group. Furthermore, the removal of the transplants on day 126 resulted in hyperglycemia, indicating that the reduction of blood glucose was dependent on the transplants. Diabetic mice transplanted with BM/islets demonstrated the longest survival period (130 vs. 40 days for those with islet-only transplants). The transplanted BM/islets showed signs of vascularization and migration from the renal capsule into medulla. Conclusions. Our results suggest that BM precultured with human islets may enhance the survival and function of transplanted islets, thus significantly improving the therapeutic efficacy of islet transplantation for type 1 diabetes.

Original languageEnglish
Pages (from-to)801-809
Number of pages9
JournalTransplantation
Volume95
Issue number6
DOIs
StatePublished - May 27 2013

Fingerprint

Bone Marrow
Islets of Langerhans Transplantation
Survival
Transplants
Capsules
Insulin
SCID Mice
Type 1 Diabetes Mellitus
Hyperglycemia
Blood Glucose
Transplantation
Kidney

Keywords

  • Allogeneic bone marrow
  • Diabetes
  • Human islets

ASJC Scopus subject areas

  • Transplantation

Cite this

Allogeneic bone marrow cocultured with human islets significantly improves islet survival and function in vivo. / Luo, John Z Q; Xiong, Fang; Al-Homsi, A. Samer; Ricordi, Camillo; Luo, Luguang.

In: Transplantation, Vol. 95, No. 6, 27.05.2013, p. 801-809.

Research output: Contribution to journalArticle

Luo, John Z Q ; Xiong, Fang ; Al-Homsi, A. Samer ; Ricordi, Camillo ; Luo, Luguang. / Allogeneic bone marrow cocultured with human islets significantly improves islet survival and function in vivo. In: Transplantation. 2013 ; Vol. 95, No. 6. pp. 801-809.
@article{fcd99fbe41f74c40aa23bfb47b7a2d0c,
title = "Allogeneic bone marrow cocultured with human islets significantly improves islet survival and function in vivo",
abstract = "Background. A significant barrier to islet transplantation is the rapid loss of human islet function in vivo. The present study evaluates whether bone marrow (BM) could be used to support human islet survival and function in vivo. Methods. We cocultured human islets and BM for 3 weeks before transplantation into the left subrenal capsule of diabetic severe combined immunodeficient mice. Results. The cocultured human islets before transplantation demonstrated improved viability, increased size, and migration capacity in vitro. After 4 months, animals transplanted with precultured BM/islets exhibited euglycemia and detectable human insulin levels (157 KU/mL), whereas no human insulin was detected in the islet-only transplantation group. Furthermore, the removal of the transplants on day 126 resulted in hyperglycemia, indicating that the reduction of blood glucose was dependent on the transplants. Diabetic mice transplanted with BM/islets demonstrated the longest survival period (130 vs. 40 days for those with islet-only transplants). The transplanted BM/islets showed signs of vascularization and migration from the renal capsule into medulla. Conclusions. Our results suggest that BM precultured with human islets may enhance the survival and function of transplanted islets, thus significantly improving the therapeutic efficacy of islet transplantation for type 1 diabetes.",
keywords = "Allogeneic bone marrow, Diabetes, Human islets",
author = "Luo, {John Z Q} and Fang Xiong and Al-Homsi, {A. Samer} and Camillo Ricordi and Luguang Luo",
year = "2013",
month = "5",
day = "27",
doi = "10.1097/TP.0b013e31828235c7",
language = "English",
volume = "95",
pages = "801--809",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Allogeneic bone marrow cocultured with human islets significantly improves islet survival and function in vivo

AU - Luo, John Z Q

AU - Xiong, Fang

AU - Al-Homsi, A. Samer

AU - Ricordi, Camillo

AU - Luo, Luguang

PY - 2013/5/27

Y1 - 2013/5/27

N2 - Background. A significant barrier to islet transplantation is the rapid loss of human islet function in vivo. The present study evaluates whether bone marrow (BM) could be used to support human islet survival and function in vivo. Methods. We cocultured human islets and BM for 3 weeks before transplantation into the left subrenal capsule of diabetic severe combined immunodeficient mice. Results. The cocultured human islets before transplantation demonstrated improved viability, increased size, and migration capacity in vitro. After 4 months, animals transplanted with precultured BM/islets exhibited euglycemia and detectable human insulin levels (157 KU/mL), whereas no human insulin was detected in the islet-only transplantation group. Furthermore, the removal of the transplants on day 126 resulted in hyperglycemia, indicating that the reduction of blood glucose was dependent on the transplants. Diabetic mice transplanted with BM/islets demonstrated the longest survival period (130 vs. 40 days for those with islet-only transplants). The transplanted BM/islets showed signs of vascularization and migration from the renal capsule into medulla. Conclusions. Our results suggest that BM precultured with human islets may enhance the survival and function of transplanted islets, thus significantly improving the therapeutic efficacy of islet transplantation for type 1 diabetes.

AB - Background. A significant barrier to islet transplantation is the rapid loss of human islet function in vivo. The present study evaluates whether bone marrow (BM) could be used to support human islet survival and function in vivo. Methods. We cocultured human islets and BM for 3 weeks before transplantation into the left subrenal capsule of diabetic severe combined immunodeficient mice. Results. The cocultured human islets before transplantation demonstrated improved viability, increased size, and migration capacity in vitro. After 4 months, animals transplanted with precultured BM/islets exhibited euglycemia and detectable human insulin levels (157 KU/mL), whereas no human insulin was detected in the islet-only transplantation group. Furthermore, the removal of the transplants on day 126 resulted in hyperglycemia, indicating that the reduction of blood glucose was dependent on the transplants. Diabetic mice transplanted with BM/islets demonstrated the longest survival period (130 vs. 40 days for those with islet-only transplants). The transplanted BM/islets showed signs of vascularization and migration from the renal capsule into medulla. Conclusions. Our results suggest that BM precultured with human islets may enhance the survival and function of transplanted islets, thus significantly improving the therapeutic efficacy of islet transplantation for type 1 diabetes.

KW - Allogeneic bone marrow

KW - Diabetes

KW - Human islets

UR - http://www.scopus.com/inward/record.url?scp=84877602612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877602612&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e31828235c7

DO - 10.1097/TP.0b013e31828235c7

M3 - Article

C2 - 23416682

AN - SCOPUS:84877602612

VL - 95

SP - 801

EP - 809

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 6

ER -